Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valchlor

- PMLiVE

AZ nears EU approval for hyperkalaemia drug Lokelma

CHMP adopts positive opinion for the potassium-binding treatment

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

Actelion HQ Switzerland

J&J agrees $30bn deal to acquire Actelion

Swiss biotech to retain control of early-stage pipeline as J&J takes minority stake in R&D spin-out

Actelion HQ Switzerland

Actelion reports late-stage trial failure as J&J talks continue

MAESTRO trial results disappointing but unlikely to lead to a breakdown in talks

- PMLiVE

Celgene bid to push Revlimid beyond myeloma blocked again

Cancer treatment fails phase III trial in lymphoma

- PMLiVE

J&J back in frame to buy Actelion after Sanofi talks break down

Parties now in exclusive negotiations about a possible deal

Deal Watch November 2016

Actelion, Allergan, Johnson & Johnson, Novartis and more feature in this month's pharma deals round-up

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

Actelion HQ Switzerland

J&J abandons talks with Actelion as another suitor circles

Biotech said to be holding out for a higher offer as speculation of Sanofi interest builds

Actelion HQ Switzerland

Resurgent Actelion catches J&J’s eye

Confirms talks of possible take over after Uptravi sees ‘outstanding’ sales

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

CHMP recommends Merck & Co’s Lantus biosimilar

Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links